ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), reported that it has acquired 31 previously marketed generic drug products from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) for $12.5 million in cash and a percentage of future gross profits from product sales.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
The acquisition includes 20 solid-oral immediate release products, 4 extended release products and 7 liquid products. ANI will begin work immediately on transferring these products into its manufacturing facilities in anticipation of product launches beginning in the fourth quarter of 2014.
All of these products have been previously approved by FDA as abbreviated new drug applications (ANDAs). The total current annual market for these products is $860 million per IMS Health.
ANI’s products include an FDA-approved testosterone gel, which is licensed to Teva Pharmaceuticals USA.
Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals, stated, “This acquisition is a significant opportunity for ANI to expand our generic product portfolio beyond our current seven marketed products.
When launched, these products will strengthen our business by growing our revenue base and leveraging our manufacturing capabilities. We are excited that this transaction extends the ANI-Teva relationship beyond the existing generic testosterone gel partnership.”
Over the last two years ANI has launched three new products and has twelve products in development. ANI’s targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities.